Archived Facts

Posts Tagged ‘diagnostics’

New York, US (PRWEB) July 19, 2012

The primary reason for translating packaging for medical devices and diagnostics to be sold overseas is to ensure that the products can be used safely and as intended. Many medical devices and diagnostics businesses are now embarking upon translation projects to take advantage of the huge demand in regions such as Asia, South America and Africa.

Datamonitor predicts that by 2015, the global healthcare equipment and supplies market will be worth $ 370.7 billion, which is up 13.4 percent from the industrys value in 2010. Although the US still accounts for 45 percent of this market, there are several growing markets in emerging economies such as the BRIC nations and Africa. Therefore, it makes economic sense for healthcare and medical device firms to carefully translate the packaging and documentation of their products to a range of languages whether it is Portuguese, French, Cantonese or Hindi.

Proper translation is a vital part of the process of bringing medical products into foreign markets. Whether it is a consumer buying a device such as a hearing aid, a nurse administering an infusion pump or a surgeon implanting a stent, they preferably need to be able to read the packaging and directions in their own language. Medical device firms cannot afford mistakes in terminology in the translation process and the same can be said for medical diagnostics companies. Accurate translation is essential and cannot be compromised.

Medical device firms entering new markets do find that they are faced with growing regulatory pressures and this is where working with a qualified language services provider can help. The US Food and Drug Administration is keen to stress the importance of accurate and high-quality translation of medical device packaging. It states that medical device firms should work on, establishing and maintaining design transfer procedures that insure that the package design is correctly translated into production specifications.

It also asserts that manufacturers of other Class I devices should establish and maintain procedures for ensuring that their device design is correctly translated into production specifications.

In light of the regulatory demands and the pressure to constantly accelerate time-to-market for medical devices and diagnostics products, working with a language services provider with expertise in the medical device field can help. Translating medical device and diagnostics packaging is a high-risk activity that requires a huge level of expertise and experience to ensure best practice is observed. With short product-development cycles and increasing time pressures, medical technologies manufacturers cant risk putting speed above quality. Inaccurate and faulty translation could lead to expensive product recalls or liability cases.

Working with a qualified language service provider that holds internationally recognized quality standards, including ISO 13485:2003 and 14971:2007 certifications, is an effective way to reduce exposure when embarking upon a medical device, diagnostics and related services translation project. Merrill Brinks medical devices and diagnostics translation services offer a world-class, end-to-end solution that ensures medical device firms can get their products to new markets accurately and within budget.

Merrill Brinks translation professionals are subject matter experts with experience in translating medical device and diagnostics packaging. They have linguists with expertise in diverse subjects such as vision care, orthopaedics, neurology, urology, vascular surgery and cardiology – equipping them with the background knowledge necessary to produce accurate translations of even the most complex and technical medical terminology.

About Merrill Brink International

Merrill Brink International (http://www.merrillbrink.com) is a leading provider of complete translation and language solutions for global companies and law firms, with special expertise in serving the legal, financial, life sciences, software, heavy machinery and corporate markets. A proven leader with more than 30 years of experience, Merrill Brink offers a wide range of language solutions including translation, localisation, desktop publishing and globalisation services.

Merrill Brink is recognised in the industry for its commitment to quality and its pioneering approach of leveraging technology to reduce costs, eliminate redundant processes and accelerate translation life cycles. Merrill Brink is certified to ISO 9001:2008; ISO 27001:2005 and ISO 13485:2003, and registered to EN 15038:2006 and ISO 14971:2007. Together, these standards provide assurance that the most stringent process and quality standards for translation are followed. Merrill Brink International is a wholly owned subsidiary of Merrill Corporation.

For more information, please contact Merrill Brink at eurosales(at)merrillbrink(dot)com or in Europe, call 353-(0)91-393000 or in the U.S., call 800-688-4400; Web: http://www.merrillbrink.com

For full text: http://www.merrillbrink.com/packaging-translation-for-the-medical-device-and-diagnostics-07162012.htm

Follow us on Twitter: @merrillbrink







Related Posts:

Yorba Linda, CA (PRWEB) March 28, 2012

BioConference Live, the world’s largest producer of online-only conferences, is bringing together the clinical diagnostics community for this groundbreaking virtual conference that kicks off Wednesday May 23rd at 10:00 AM Eastern Standard Time. The conference will continue for two days through Thursday May 24th at 10:00 PM Eastern Standard Time. This is a Continuing Education program accredited by the AACC ACCENT, so attendees can earn free CE Credits.

BioConference Live features live, video keynote presentations where attendees can have their questions answered by presenters in real time. The event features a virtual exhibit hall and a networking lounge to interact with world renowned experts and colleagues. BioConference Live is conveniently held online for free, and is easily accessed from any computer, making it time efficient and cost effective to attend. Participants will be able to:


Search and attend session(s) of their choice
Have their questions answered in real-time by experts via live videos
Receive Free Continuing Education Credits accredited by the AACC ACCENT
Chat live with peers and speakers
Browse a virtual exhibit floor for solution providers

BioConference Live will bring together clinicians, doctors, medical experts, lab directors and professionals from around the world to learn about recent advances in clinical diagnostics. The topics of the 2012 conference consist of Infectious Disease, Oncology, Vitamin D, Cardiology, Nutrition, Laboratory Testing, Clinical Chemistry, Molecular Diagnostics, Diabetes, Point of Care, Allergy, Hematology, and much more. Speakers include:

Michael Dugan, MD, Chief Medical Officer, Roche Molecular Diagnostics
Marc Redman, MBA, Vice President – Chemistry & Immunoassays, Diagnostics Division, Siemens Healthcare
Robert Hamilton, PhD, DABMLI, Professor of Medicine and Pathology, Johns Hopkins University School of Medicine, Director, Johns Hopkins Dermatology, Allergy and Clinical Immunology Reference Laboratory
Bruce Hanna, PhD, Clinical Professor of Pathology and Microbiology, NYU School of Medicine
Hubert Vesper, PhD, Chief of CDC Protein Biomarker Lab, Division of Laboratory Sciences, National Center for Environment, Centers for Disease Control and Prevention
Seth Martin, MD, Cardiology Fellow, Division of Cardiology, The Johns Hopkins Hospital
Paul Billings, MD, PhD, Chief Medical Officer, Life Technologies
Cynthia Bowman, MD, Anatomic and Clinical Pathologist, Currently Chair of CAP POCT Committee
Howard Weintraub, MD, Clinical Director of Center for the Prevention of Cardiovascular Disease, Clinical Associate Professor, New York University
Joseph Coresh, MD, PhD, Professor, Director, Cardiovascular Epidemiology & Comstock Center, Johns Hopkins University, Bloomberg School of Public Health
Paul Epner, MEd, MBA, Director, The Society to Improve Diagnosis in Medicine, Principal, Paul Epner LLC
Franco Folli, MD, PhD, Professor of Medicine, Division of Diabetes, UT Health Science Center at San Antonio
George Fritsma, MS, MT (ASCP), Teacher and Lab Practitioner, Fritsma Factor, Precision BioLogic, Associate Professor, Department of Pathology, University of Alabama at Birmingham
Wieslaw Furmaga, MD, Associate Professor, University of Texas Health Science Center at San Antonio, Pathology, Interim Medical Director, Molecular Reference Laboratory, Pathology
Eric Gluck, MD, JD, Director of Critical Care Services, Swedish Covenant Hospital
William Grant, PhD, Director, Sunlight, Nutrition and Health Research Center (SUNARC)
David Grenache, PhD, Medical Director, Special Chemistry Laboratory, Associate Professor of Pathology, University of Utah School of Medicine, ARUP Laboratories
Michael Holick, MD, PhD, Professor of Medicine, Physiology and Biophysics, Director of the General Clinical Research Center, Director of the Vitamin D, Skin and Bone Research Laboratory, Director, Biologic Effects of Light Research Center, Boston University Medical Center
Brian Jackson, MD, Associate Professor of Pathology (Clinical), Medical Director of Informatics, ARUP Laboratories, University of Utah, Department of Pathology
Steven Jones, MD, Director, Inpatient Cardiology, Assistant Professor of Medicine, Cardiology, Johns Hopkins Medicine
Allan Laurence Kennedy, MD, FRCP, Department Chair, Endocrinology, Diabetes and Metabolism, Cleveland Clinic
Gerald Kost, MD, PhD, MS, FACB, Professor, Director of Clinical Chemistry , Director, POCTCTR, School of Medicine, University of California, Davis, Director and PI, Point-of-care technologies Center, National institute of biomedical imaging and bioengineering, NIH
Matthew Krasowski, MD, PhD, Vice Chair of Clinical Affairs, University of Iowa Hospitals and Clinics, Department of Pathology
George Kudolo, PhD, Professor, Clinical Chemistry & Toxicology, University of Texas Health Science Center, Clinical Lab Sciences
Michael Laposata, MD, PhD, Director, Division of Laboratory Medicine and Clinical Laboratories, Edward and Nancy Fody Professor, Vanderbilt University
Kent Balanis Lewandrowski, MD, Pathologist, Associate Chief for Clinical Services, Massachusetts General Hospital
Randie Little, PhD, Associate Professor, Diabetes Diagnostic Laboratory, Dept. of Pathology & Anatomical Science, University of Missouri School of Medicine
Hans Loyda, PhD, Director, Clinical Development and Education, Roche Diagnostics
Giuseppina Maccarrone, PhD, Research Scientist, RG. Proteomics and Biomarkers, Max Planck Institute of Psychiatry
Gwendolyn McMillin, PhD, Associate Professor (Clinical), University of Utah Pathology, Medical Director, Associated Regional , Clinical Drug Abuse Testing, Medical Director, ARUP Laboratories, Trace Elements, Co-Medical Director, ARUP Laboratories, Pharmacogenomics
Pieter Muntendam, MD, Executive Vice President, Chief Medical Officer, BG Medicine, Inc.
James Nichols, PhD, Medical Director, Clinical Chemistry, Baystate Health, Professor of Pathology, Tufts University Scho, Tufts University School of Medicine, Baystate Health
Liron Pantanowitz, MD, Director of the Pathology Informatics Fellowship Program, Director of the FNA Clinic, Assistant Director of Cytology in the Division of Cytology at UPMC-Shadyside, Associate Professor, Pathology & Biomedical Informatics, U of Pittsburgh Medical Center, Editor-in-Chief, Journal of Pathology Informatics
Ellinor Peerschke, PhD, FAHA, Vice Chair, Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center
Christopher Price, PhD, Visiting Professor in Clinical Biochemistry, University of Oxford
Andrea Rose, PhD, MBA, Senior Clinical Support Consultant, Clinical Support, Roche Diagnostics
Kevin Rosenblatt, MD, PhD, Associate Professor, Center for Proteomics and Systems Biology, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston (UTHealth)
Erkki Ruoslahti, MD, PhD, Distinguished Professor, University of California, Santa Barbara, Sanford-Burnham Medical Research Institute (at UCSB), Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla
Mark Shirtliff, PhD, Associate Professor, Department of Microbial Pathogenesis, Dental School, Associate Professor, Dept. of Microbiology and Immunology, School of Medicine, University of Maryland School of Medicine
Wilson Tang, MD, Staff Cardiologist and Research Director, Sydell and Arnold Miller Family Heart & Vascular Institute, Associate Professor of Medicine, Lerner College of Medicine of Case Western Reserve University, Director, Cardiomyopathy Program, Cleveland Clinic
Yi-Wei Tang, MD, PhD, F(AAM), FIDSA, Chief of the Clinical Microbiology Service, Department of Laboratory Medicine, Memoria

Incoming search terms:

Related Posts:

California’s biggest provider of medical lab testing has agreed to repay the state $ 241 million for more than 15 years of overcharges to Medi-Cal, the state attorney general’s office said Thursday.

Related Posts:

Cypress Bioscience Inc. said Friday it will sell its diagnostics business to Exagen Diagnostics Inc. in a deal that could be worth more than $8 million.

See the article here:
Cypress Bioscience sells diagnostics unit for $8M

Related Posts:

Molecular Diagnostics Market Expected To Grow At A Double-Digit Pace Through 2015
MarketResearch.com has announced the addition of Business Insights’s new report “The Future of Molecular Diagnostics: Innovative technologies driving market opportunities in personalized medicine,” to their collection of In Vitro Diagnostics market reports. Molecular diagnostics, essentially the analysis of DNA and RNA at the molecular level, is a fast-growing business, made possible by the …

Read more on Medical News Today

Related Posts:

Cardiac diagnostics company Cardiac Science Corp. said Monday it will replace about 24,0000 automatic external defibrillators used by emergency first responders like police and firefighters.

More here:
Cardiac Science takes charge to replace devices

Related Posts:

GenMark Diagnostics slashed the price range for its already delayed initial public offering, dragging down the money it expects to raise by more than 21 percent, according to a filing Friday.

Read the original:
GenMark slashes expected price for IPO

Related Posts: